Scientific Programme

Provisional Scientific Programme




08.00-08.30 ePoster Presentations

(5 minute presentation, 5 minute discussion)

Chair: Niels Baekgaard (Denmark)

08.00-08.10 eP1 Positive Post-test Probability Value Of The Wells Score In Deep Vein Thrombosis Diagnostic According To Its Prevalence.

Ilya Schastlivtsev*1; Kirill Lobastov1; Sergey Tsaplin2; Nikita Burlov3; Maxim Kuznetsov4; Astanda Bargandzhiya1; Sergey Zhuravlev2; Grigory Rodoman1
1Pirogov Russian National Research Medical University, Moscow, Russia; 2Clinical Hospital No. 1 of the President’s Administration of the Russian Federation, Moscow, Russia; 3Leningrad Regional Clinical Hospital, Saint-Petersburg, Russia; 4Vitacore JSC, Kazan, Russia

08.10-08.20 eP2 24 months follow up of patients with deep vein thrombosis, treated with sulodexide as adjuvant during the acute and long term post thrombotic event.

Erasto Aldrett Lee*; Nora Lecuona Huet. Grupo de Atención Vascular Integral, San Luis Potosí, Mexico

08.20-08.30 eP3 A Novel And Breakthrough Way To Collect Thrombosis Risk Assessment Data

Atul Laddu1; Rishi Motkur1; Anish Joshi1; Nethra Pai1; Krish Raina1; Nysha Reddy1; Joseph Caprini2; Jibran Bokhary*1
1Global Thrombosis Forum (GTF,, Suwanee, USA; 2NorthShore University Health System, Evanston, USA

08.30-10.30 Abstract Session 1: VTE, Stents

(10 minute presentation, 10 minute discussion)

Chairs: Andrew Nicolades (Cyprus), Stavros Kakkos (Greece)

08.30-08.50 1.1 Hormonal contraception use and the risk of venous thromboembolism after minimally invasive varicose vein surgery: Insight from the CAPSIVS trial.

Mariya Shaldina*1; Kirill Lobastov2; Olga Dzhenina3; Denis Borsuk1; Ilya Schastlivtsev2; Astanda Bargandzhiya2; Alexey Fokin1. 1South Ural State Medical University, Chelyabinsk, Russia; 2Pirogov Russian National Research Medical University, Moscow, Russia; 3First Phlebological Center, Moscow, Moscow, Russia

Submitted for the EVF Prize

08.50-09.10 1.2 The role of rivaroxaban in the prevention of post thrombotic syndrome.

Christos Karathanos*; Konstantinos Spanos; Georgios Volakakis; Athanasios Chaidoulis; Konstantinos Tzimas-Dakis; Alexandros Barpatis; Konstantinos Mpatzalexis; Georgios Kouvelos; Miltiadis Matsagas; Athanasios Giannoukas. University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessa, Larissa, Greece

09.10-09.30 1.3 Non-invasive molecular MR imaging enables staging of fibrosis and monitoring response to statin treatment in the deep vein thrombosis.

Ling Gao*1; Nadia Chaher2; Joana P Cartaxo Serralha1; Carlos Velasco1; Gastão Cruz3; Claudia Prieto1; Claudia Prieto4; René M Botnar1; René M Botnar4; Alberto Smith1; Alkystis Phinikaridou1; Prakash Saha1. 1King’s College London, London, UK; 2King’s College London, London, UK; 3University of Michigan, Michigan, USA; 4Pontificia Universidad Católica de Chile, Santiago, Chile

09.30-09.50 1.4 Comparison of oral rivaroxaban and warfarin in patients with inferior vena cava filter: a retrospective cohort study.

Ilya Schastlivtsev*1; Alexey Pankov2; Sergey Tsaplin2; Eugeniy Stepanov1; Sergey Zhuravlev2; Kirill Lobastov1. 1Pirogov Russian National Research Medical University, Moscow, Russia; 2Clinical Hospital No. 1 of the President’s Administration of the Russian Federation, Moscow, Russia

09.50-10.10 1.5 Five-year outcomes of dedicated venous stents for the treatment of acute and chronic iliofemoral venous obstructive disease.

Rachael Morris*1; Anna Pouncey2; Kanoklada Srikuea1; Narayan Karunanithy1; Narayanan Thulasidasan1; Prakash Saha1; Taha Khan1; Stephen Black1. 1St Thomas’ Hospital, London, UK; 2Imperial College, London, UK

Submitted for the EVF Prize

10.10-10.30 1.6 Deep venous stent failure: the St Thomas’ classification and predictors of reintervention in chronic disease.

Ehsanul K Choudhury*1; Rachael I Morris1; Anna L Pouncey2; Kanoklada Srikuea3; Taha Khan1; Bhavesh Natha1; Narayanan Thulasidasan1; Narayan Karunaninthy1; Stephen A Black1. 1St. Thomas’ Hospital, Guy’s & St. Thomas’ NHS Foundation Trust, London, UK; 2Imperial College London, London, UK; 3Thammasat University Hospital, Pathum Thani, Thailand

Submitted for the EVF Prize

10.30-11.00 Refreshments. Visit Exhibition
11.00-13.00 Abstract Session 2: Varicose Veins

(10 minute presentation, 10 minute discussion) Chairs: Marianne Vandendreissche (Belgium), Eberhard Rabe (Germany)

11.00-11.20 2.1 Ten-year outcomes of a randomised controlled trial of endovenous laser ablation versus conventional surgery for great saphenous varicose veins.

Abduraheem Mohamed*1; Daniel Carradice1; Ian Chetter1; George Smith1; Tom Wallace2; Shivani Rae1; Bharadhwaj Ravindhran1; Arthur Lim1; Alexander Knighton1. 1Hull York Medical School, Hull, UK; 2Leeds General Infirmary, Leeds, UK

Submitted for the EVF Prize

11.20-11.40 2.2 Synchronous prophylactic ablation of the AASV in patients undergoing thermal GSV ablation significantly reduces the recurrence rate – 12-month follow-up data for the SYNCHRONOUS Trial.

Tobias Hirsch*1; Carmen Dietrich2; Karsten Hartmann3; Thomas Mattausch4; Philipp Zollmann5; Hans-Christian Wenzel4; Jürgen Veltmann6; Thomas Weiler7; Guido Lengfellner8; Lars Müller9; Felizitas Pannier10; Lorenz Uhlmann2; Markus Stücker11; Christine Müller-Christmann2

1Practice for Internal Medicine and Vascular Diseases, Halle, Germany; 2University of Heidelberg, Heidelberg, Germany; 3Vein Center Freiburg, Freiburg, Germany; 4Vein Center Leipzig, Leipzig, Germany; 5Venenzentrum Zollmann, Jena, Jena, Germany; 6Venenzentrum Dr. Zollmann, Jena, Jena, Germany; 7Venencentrum Pfortzheim, Pfortzheim, Germany; 8Venenzentrum Dr. Lengfellner und Koll. Regensburg, Regensburg, Germany; 9Dermatologicum Hamburg, Hamburg, Germany; 10Privatpraxis Dr. Pannier, Bonn, Germany; 11University of Bochum, Bochum, Germany

11.40-12.00 2.3 Patterns of recurrence in recurrent varices after surgery (REVAS): A systematic review and network meta-analysis.

Konstantinos Kavallieros*; Giannis Konstantinou; Emmanuel Giannas; Iris Soteriou; Turner Benedict; Adam Gwozdz; Alun Davies. Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, UK

Submitted for the EVF Prize

12.00-12.20 2.4 Impact of thermographic imaging on clinical decision making for patients with superficial venous disease.

Fedor Lurie*1; Kate Gates2. 1Jobst Vascular Institute and the University of Michigan, Toledo, USA; 2Jobst Vascular Institute, Toledo, USA

12.20-12.40 2.5 Role of compression after radiofrequency ablation of varicose veins: longer term follow-up of randomised controlled trial.

Chee Yee Hew*1; Damien Mcelvenny2; Madu Onwudike3. 1Manchester University NHS Foundation Trust, Manchester, UK; 2Centre for Occupational and Environmental Health, University of Manchester, Manchester, UK; 3Bolton Hospitals NHS Foundation Trust, UK, Manchester, UK

Submitted for the EVF Prize

12.40-13.00 2.6 Endovenous welding: 5-year experience of using a new thermal method with automatic ablation mode.

Larysa Chernukha*1; Vladyslav Horbovets2; Sofiia-Solomiia Horbovets2; Melnychuk Hlib2. 1Shalimov National Institute of Surgery and Transplantology of NAMS of Ukraine, Kyiv, Ukraine; 2Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine

13.00-14.00 Lunch. Visit Exhibition
14.00-15.00 Industry Session 1
15.00-16.00 Didactic Session 1: Venous Thromboembolism, AI

Chairs: Armando Mansilha (Portugal), Tomasz Urbanek (Poland)

15.00-15.15 The controversy on treating calf DVT. Stavros Kakkos (Greece)
15.15-15.30 What is the destiny of the deep femoral vein after iliofemoral thrombus removal. Niels Baekgaard (Denmark)
15.30-15.45 Thrombus extraction versus thrombolysis. Efthymios Avgerinos (Greece)
15.45-16.00 The use of artificial intelligence (AI) in phlebology today and tomorrow. Albert Claude Benhamou (France)
16.00-16.30 Refreshments and Visit Exhibition
16.30-17.30 Industry Session 2
17.30-18.30 Didactic Session 2: Post-thrombotic Syndrome

Chairs: Efthymios Avgerinos (Greece), Marzia Lugli (Italy)

17.30-17.45 Can we prevent PTS? Tomasz Urbanek (Poland)
17.45-18.00 Pelvic congestion syndrome. Mark Whiteley (UK)
18.00-18.15 Complex cases of reflux and obstruction. Houman Jalaie (Germany)
18.15-18.30 Organising a wound treatment centre in 2024 for vascular surgeons and phlebologists. Arkadiusz Jawien (Poland)
18.30-19.30 Welcome Reception



08.00-08.30 ePoster Presentations

(5 minute presentation, 5 minute discussion)

Chair: Erica Mendoza (Germany)

08.00-08.10 eP4 Prevalence Of Chronic Venous Disease And Quality Of Life In The Greek Population.
Efthymios D Avgerinos*1; Spyros N Vasdekis2; Dimitrios G Kardoulas2; Garyfallia Stefanou3; Georgia Kourlaba4; Antonios Papageorgiou5
1Attikon Hospital, University of Athens and Athens Medical Center, Athens, Greece; 2Attikon Hospital, University of Athens, Athens, Greece; 3EconCare LP, Athens, Greece; 4University of Peloponnese, Athens, Greece; 5Athens Navy Hospital, Athens, Greece
08.10-08.20 eP5 Efficacy Of Micronized Purified Flavonoid Fraction (MPFF) In Reducing Lower-limb Symptoms In Patients At All Stages Of Chronic Venous Disease: A Systematic Literature Review And Meta-analysis.
Stavros Kakkos1; Kirill Lobastov2; Alejandro Ochoa Gonzalez3; Sriram Narayanan4; Lianrui Guo5; Andrew Nicolaides*6
1University of Patras Medical School, Patras, Greece; 2Pirogov Russian National Research Medical University, Moscow, Russia; 3Hospital Centro Medico del Noroeste, San Luis Río Colorado, Mexico; 4The Harley Street Heart and Vascular Centre, Singapore, Singapore; 5Xuanwu Hospital, Capital Medical University, Beijing, China; 6Vascular Screening and Diagnostic Centre and University of Nicosia Medical School, Nicosia, Cyprus
08.20-08.30 eP6 Professional Liability And Patient Safety In Thromboembolic Disease.
Mar Oller Grau*1; Enric Roche Rebollo1Hospital General de Catalunya, Barcelona, Spain; 2Hospital Universitari General de Catalunya, Barcelona, Spain
08.30-10.30 Abstract Session 3: Miscellaneous

(10 minute presentation, 10 minute discussion)

Chairs: Albert-Claude Benhamou (France), Marianne Vandendriessche (Belgium)

08.30-08.50 3.1 Short term cost effectiveness of radiofrequency ablation and high ligation/stripping for great saphenous vein incompetence.

Oskar Nelzén*1; Johan Skoog2; Lars Bernfort3; Helene Zachrisson4. 1Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Linköping, Sweden; 22Department of Clinical Physiology in Linköping, and Department of Health, Medicine and Caring Scien, Linköping, Sweden; 3Department of Health, Medicine and Caring Sciences, Linköping, Sweden; 4Department of Clinical Physiology in Linköping, and Department of Health, Medicine and Caring Science, Linköping, Sweden

08.50-09.10 3.2 The DAVE randomised clinical trial — decellularised dermis allograft for the treatment of chronic venous leg ulceration.

Matthew Tan*1; Sarah Onida1; Valeria Balan1; Francine Heatley1; Sarrah Peerbux1; Tristan Lane1; David Epstein2; Keith Poskitt3; Nicky Cullum4; John Norrie5; Robert Lee5; Akila Chandrasekar6; Richard Lomas6; Alun Davies1. 1Imperial College London, London, UK; 2University of Granada, Granada, Spain; 3Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, UK; 4University of Manchester, Manchester, UK; 5University of Edinburgh, Edinburgh, UK; 6NHS Blood and Transfusion, Bristol, UK

Submitted for the EVF Prize

09.10-09.30 3.3 An open-label first in man usability and safety investigation with an intravenous injection technique to deploy tumescence during laserablation of the great saphenous vein.

Michael Akesson*1; Anders Lundell2. 1Department of Clinical Sciences Lund, Lund University, Sweden., Malmo, Sweden; 2Lund University, Lund, Sweden

09.30-09.50 3.4 3 years experience and follow up of varixio foam ecoguided procedure in great saphenous veins and tributaries.

Giovanni Alongi*; Giovanni Alongi. Angiocor, Palermo, Italy

Submitted for the EVF Prize

09.50-10.10 3.5 Status of the superficial lymphatic system in patients with chronic venous disease as detected by ICG-lymphography.

Marina Demekhova*1; Kirill Lobastov2; Igor Sonkin3; Tatiyana Gurina4; Astanda Bargandzhiya2. 1NMRC of Oncology named after N.N.Petrov of MoH of Russia, Saint Petersburg, Russia; 2Pirogov Russian National Research Medical University, Moscow, Russia; 3Road Clinical Hospital of JSC “Russian Railways”, Saint Petersburg, Russia; 4Phlebocentr Private Clinic, Kaliningrad, Russia

Submitted for the EVF Prize

10.10-10.30 3.6 Investigating the role of LL37 in accelerating atherosclerosis following venous thrombosis.

Joana P. Cartaxo Serralha*1; Ling Gao1; Maria L. Bertolaccini1; Alexandru Dregan1; Joachim Pircher2; Alkystis Phinikaridou1; Christian Schulz2; Alberto Smith1; Prakash Saha1. 1King’s College London, London, UK; 2Klinikum der Universität München, Munich, Germany

Submitted for the EVF Prize

10.30-11.00 Refreshments
11.00-12.00 Industry Session 3
12.00-12.30 EVF Invited Lecture:
  Introduction: Stavros Kakkos (Greece)
  Perioperative Management of Patients on Vitamin K Antagonists and Direct Oral Anticoagulants: Present and Future Perspectives. Alex Spyropoulos (USA)
12.30-13.30 Lunch. Visit Exhibition
13.30-14.10 Prize winning papers from the American Vein and Lymphatic Society and Japanese Society of Phlebology

(10 minute presentation, 10 minute discussion)

Chairs: Stephen Black (UK), Mark Malouf (Australia)

13.30-13.50 Pr1 Identification of Outcomes in Clinical Studies for Pelvic Venous Disease: A Scoping Review.

Adam Gwozdz. Department of Surgery, Imperial College London, UK

13.50-14.10 Pr2 Investigation of risk point of the great saphenous vein-saphenous nerve in the treatment of lower extremity varicose veins.

Katsushi Oda*.  Kochi Vein Care Clinic, Kochi, Japan

14.10-14.30 International Guidelines 2024 on VTE: Highlights and Controversies. Andrew Nicolaides (Cyprus)
14.30-15.30 Industry Session 4
15.30-16.00 Refreshments and Visit Exhibition
16.00-17.30 Joint EVF/AVF/ESVS/ Session

Chairs: George Geroulakos (Greece), Ruth Bush (USA)

  AVF Leadership:
16.00-16.15 Influence of SFJ reflux on venous symptomatology: Current and future research. Ruth Bush (USA)
16.15-16.30 Recognition of the anterior accessory saphenous vein in primary and recurrent venous disease. Kathleen Ozsvath (USA)
  ESVS Leadership:
16.30-16.45 Misconceptions regarding elastic compression in DVT patients for prevention of PTS. Armando Mansilha (Portugal)
16.45-17.00 Long term freedom from recurrent superficial venous disease after thermal ablation, open surgery, foam sclerotherapy and mechanochemical ablation. Maarit Venermo (Finland)
  EVF Leadership
17.00-17.15 High risk superficial vein thrombosis. Athanasios Giannoukas (Greece)
17.15-17.30 Complications of interventions and recurrence. Imre Bihari (Hungary)
17.30-17.45 Invited Presentation: Comparing cyanoacrylate sealing closure with thermal ablation and surgical stripping: first results of the SPECTRUM Study programme. Tobias Hirsch (Germany)
17.45-18.45 Annual General Meeting (members only)
20.00 Congress Dinner



08.00-08.30 ePoster Presentations

(5 minute presentation, 5 minute discussion)

Chair: Efthymios Avgerinos (Greece)

08.00-08.10 eP7 A First In Human Study: In-vivo Venous Leg Ulcer Metabolomic Profiling Using A Rapid Evaporative Ionisation Mass Spectrometry (REIMS) Coupled With The Hydrosurgical Debridement System
Kanin Pruekprasert*; Matthew Tan; Daniel Simon; Lauren Ford; Alun Davies; Zoltan Takats; Sarah Onida. Imperial College London, London, UK
08.10-08.20 eP8 Atypical Forms Of Lower Limb Varicose Veins
Nina Mzhavanadze*; Roman Kalinin; Igor Suchkov; Kristina Pshennikova; Viktor Korbut; Ruslan Khashumov; Ivan Shanaev.
Ryazan State Medical University, Ryazan, Russia
08.30-08.30 eP9 Reversal Of Age-related Endothelial Dysfunction In The Arterial And Venous Vasculature In Rats By Micronized Purified Flavonoid Fraction (MPFF) With Improvement Of The Nitric Oxide/Reactive Oxygen Species Imbalance
Said Amissi1; Hira Muzammel1; Ali Mroueh1; Ibrahima Diouf1; Dalseong Gong1; Walaa Fakih1; Abdul Qureshi1; Eric Mayoux2; Valérie Schini-Kerth*1Strasbourg University, Strasbourg, France; 2Institut de Recherche International Servier, Suresnes, France
08.30-10.30 Abstract Session 4: PTS, Haemodynamics of Iliac Occlusion, Venoactive Drugs

10 minute presentation, 10 minute discussion)

Chairs: Marzia Lugli (Italy)

08.30-08.50 4.1 Non-operative management of post thrombotic syndrome: a systematic review and meta-analysis of the evidence from 2000-2023.

Ehsanul K Choudhury*1; Alena Abraham2; Elif I Okten2; Taha Khan1; Stephen A Black1. 1St. Thomas’ Hospital, Guy’s & St. Thomas’ NHS Foundation Trust, London, UK; 2King’s College London, London, UK

08.50-09.10 4.2 Incidence and treatment of pelvic congestion syndrome in patients with varicose veins.

Christos Dimopoulos*1; Ioannis Papastefanou2; Panagiotis Theodoridis1; Nikolaos Iatrou1; Theodosios Bisdas1. 1Athens Medical Center, Athens, Greece; 2King’s College London, London, UK

09.10-09.30 4.3 Direct measurement of the hemodynamic impact of iliac vein stenosis: a pre-clinical study.

Fedor Lurie*1; Todd Russell2; Yusuf Nawras3. 1Jobst Vascular Institute and the University of Michigan, Toledo, USA; 2Jobst Vascular Institute, Toledo, USA; 3University of Toledo, Toledo, USA

09.30-09.50 4.4 Acquired arteriovenous fistulas in patients with symptomatic chronic iliac vein occlusion.

Yuji Hoshino*; Hiroyoshi Yokoi. Fukuoka Sanno Hospital, Fukuoka, Japan

09.50-10.10 4.5 Vitis vinifera leaf extract improves the quality of life in patients with chronic venous insufficiency (CVI): a prospective, randomized, double-blind, controlled study.

Foteini Psachoulia*1; Christos Karathanos2; Georgios Sfyroeras1; Konstantinos Antonopoulos1; Georgios Kouvelos2; Dimitrios Kardoulas1; Christina Chania3; Christina Petropoulou3; Aikaterini Argyropoulou3; Phaedra-E. Bokari3; Miltiadis Matsagkas2; Nikolaos Adamopoulos4; Alexios-L. Skaltsounis3; Ioannis Kakisis1; Athanasios Giannoukas2; Ioanna Andreadou3; Georgios Geroulakos1. 1Athens University Medical School, Attikon University Hospital, Athens, Greece; 2Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Larissa, Greece; 3National and Kapodistrian University of Athens (NKUA), Athens, Greece; 4Galenica S.A., Athens, Greece

10.10-10.30 4.6 Effectiveness of micronized purified flavonoid fraction-based treatment in patients with chronic venous disease: meta-analysis of data from vein act prolonged observational studies.

Vadim Bogachev*1; Boris Kvasnikov2; Olga Linnik2. 1Pirogov Russian National Research Medical University, Moscow, Russia; 2Servier, Moscow, Russia

10.30-11.00 Refreshments and Visit Exhibition
11.00-12.00 Joint EVF/BVF Session

Chairs: Athanasios Giannoukas (Greece), Sorin Olariu (Romania)

11.00-11.15 Crossectomy. Dominik Heim (Switzerland)
11.15-11.30 Complications and adverse events in superficial venous treatments. Christos Karathanos (Greece)
11.30-11.45 Conservative treatment vs thrombus removal for Iliofemoral vein thrombosis in patients with congenital abnormalities of the inferior vena cava. Vangelis Alexiou (Greece)
11.45-12.00 Differences in the diagnosis and management of FAVA and glomuvenous malformations. George Geroulakos (Greece)
12.00-13.00 Didactic Session 3 / Abstract Session 5: New Devices, Varicose Veins and Technology

(10 minute presentation, 5 minute discussion)

Chairs: Erika Mendoza (Germany), Eberhard Rabe (Germany)

12.00-12.15 News on foam, screening, tumescence and ulcer healing. Dominik Heim (Switzerland) There is an undercurrent of cyanoacrylate adhesive ablation opposition out there. Is there a problem with glue? Mark Malouf (Australia)
12.30-12.45 5.3 3D ultrasound: applications of new technology in the study of venous pathology.

Edoardo Cervi*1; Giovanni Alongi2; Mattia Paletti3; Marika Delai4. 1Università degli Studi di Brescia, Brescia, Italy; 2Angiocor, Messina, Palermo, Agrigento, Italy; 3Poliambulanza, Brescia, Italy; 4University of Brescia, Brescia, Italy

12.45-13.00 5.4 High intensity focused ultrasound in treating great saphenous vein incompetence: perioperative and 1-year outcomes.

Paolo Casoni*1; Emanuele Nanni1; Matteo Pizzamiglio2. 1Ippocrate vein Academy, PARMA, Italy; 2Ippocrate Vein Academy, Parma, Italy

13.00-14.00 Lunch and Visit Exhibition
14.00-15.00 Didactic Session 4: Varicose Veins, Imaging, Stenting

Chairs: Niels Baekgaard (Denmark), Dominik Heim (Switzerland)

14.00-14.15 Anatomy of lower extremity veins – should we revise the undergraduate teaching? Marian Simka (Poland)
14.15-14.30 The anatomy of the anterior accessory saphenous vein. Alberto Caggiati (Italy)
14.30-14.45 The benefits of 3D imaging in phlebology. Mario Sica (France)
14.45-15.00 Current status of stenting in chronic iliofemoral obstruction. Stephen Black (UK)
15.00-16.00 Abstract Session 6: Miscellaneous

(10 minute presentation, 5 minute discussion)

Chairs: Imre Bihari (Hungary), Stavros Kakkos (Greece)

15.00-15.15 6.1 Preclinical chronic animal study to evaluate percutaneous selective closure or percutaneous closure combined with foam injection in superficial veins.

Edoardo Cervi*1; Gastone Bergamaschi2. 1Università degli Studi di Brescia, Brescia, Italy; 2Garofalo Health Care Clinic, Vicenza, Italy

15.15-15.30 6.2 Inflammatory and apoptotic markers in Covid-19 patients on anticoagulant therapy

Igor Suchkov*; Roman Kalinin; Andrey Agapov; Nina Mzhavanadze; Vladislav Povarov; Aleksandr Nikiforov; Denis Maksaev; Artyom Chobanian. Ryazan State Medical University, Ryazan, Russia

15.30-15.45 6.3 An evidence based anatomical classification of incompetent calf perforator veins using ultrasound analysis of over 10,000 individual vessels.

Barrie Price*; Tim Fernandez-Hart; Charmaine Harrison; Judy Holdstock; Mark Whiteley. The Whiteley Clinic, Guildford, UK

15.45-16.00 6.4 Early results of the treatment for saphenous incompetence using cyanoacrylate glue together with foam sclerotherapy.

Marian Simka*. University of Opole, Opole, Poland

16.00-16.30 End of Meeting. Presentation of 2025 Meeting. Tomasz Urbanek (Poland)

Comments are closed.